Siri Lagethon Heck

[Siri Lagethon Heck @siri_lh]

In the PRADA trial, there was a marked difference in incidence of mild, asymptomatic CTRCD when defined by cTnT vs cTnI and sex-specific vs sex-neutral 99th percentiles URLs during adjuvant breast cancer therapy @AlbulenaMecinaj @Gulati_Norway @OmlandRn @CRG_Norway @Ahus_no

[JACC Journals @JACCJournals]

The incidence of mild, asymptomatic CTRCD according to the recent IC-OS definition was high during adjuvant therapy for early breast cancer and driven mainly by cTn elevation. https://t.co/dSYifRkVj7

#JACCCardioOnc #CardioOnc #BCsm @siri_lh

[Siri Lagethon Heck @siri_lh]

Great talk by @OmlandRn on new insights on treatment and prevention of anthracycline-induced cardiotoxicity @CRG_Norway #AHA2022 #CardioOnc

[Mike Fradley, MD @Dr_Mike_Fradley]

Let the battle begin 🤺@oncocardiology and @siri_lh debating #gdmt for #ctrcd #cardioonc #jacccardioonc #aha22

[K.G. Jebsen Center for Cardiac Biomarkers @CRG_Norway]

Grand opening of the K.G. Jebsen Center for Cardiac Biomarkers 💫 led by @OmlandRn at @Ahus_no @UniOslo_MED

Fantastic talks from the Scientific Advisory Board members @lamcardio @Vascular_Prot

Extremely grateful for this opportunity from @stiftkgj!

[VCU Health Pauley Heart Center @VCUHealthHeart]

The first major paper from our PREVENT study has been published! We're very excited to share our findings with @NEJMEvidence and the rest of the scientific community. #CVresearch #PREVENT https://t.co/UvbK6l4A4h

[Oslounivsykehus @Oslounivsykehus]

Mortality and morbidity in mild primary hyperparathyroidism: Results from a 10-year prospective randomized controlled trial of parathyroidectomy versus observation - https://t.co/4V4PfICFXY @sahlgrenska @forskningsradet @helsesorost @UniOslo @AnnalsofIM #hyperparathyroidism

[Siri Lagethon Heck @siri_lh]

#JACCCardioOnc State-of-the-Art Review
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity
https://t.co/kPQE0rHRBd @Gulati_Norway @OmlandRn @Ahus_no

[Albulena Mecinaj @AlbulenaMecinaj]

Can sacubitril/valsartan prevent cardiotoxicity? PRADA II will assess if sacubitril/valsartan given concomitantly with early breast cancer treatment regimens including anthracyclines, with or without trastuzumab, may prevent cardiac dysfunction. @siri_lh @Gulati_Norway @OmlandRn

[Peder L. Myhre MD, PhD @pmyhre]

In our prospective CMR study 6 mo after 🏥 for #COVID19; 16% had minor and 5% major cardiac pathology

No assoc with COVID severity, but more common in pts with ⬆️ #NTproBNP & #troponin

Published in @AmericanHeartJ

@siri_lh @OmlandRn @CRG_Norway

https://t.co/WkPQzDKYfv

[Siri Lagethon Heck @siri_lh]

We are proud to present the results of the extended follow-up of the PRADA trial!
https://t.co/fFk2ahdLVF
@AlbulenaMecinaj @Gulati_Norway @OmlandRn
@Ahus_no #CircACC2021 #AHAJournals #ACC21 @AHAScience

[Circulation @CircAHA]

PRADA: Candesartan improves LVEDV and GLS in long-term f/u after anthracycline use for breast cancer , but did not prevent EF decline https://t.co/BCVcm7G0BH #CircACC2021 #AHAJournals #ACC21 @AHAScience

[Albulena Mecinaj @AlbulenaMecinaj]

VCOS live with the PRADA team @ICOSociety @Gulati_Norway @siri_lh @Torbjørn Omland